Reata Pharma (RETA) Tops Q3 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Reata Pharma (RETA) Tops Q3 EPS by 10c

Reata Pharmaceuticals, Inc. Announces Third Quarter 2016 Financial and Operating Results

November 14, 2016 8:30 AM EST

IRVING, Texas, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (Reata or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2016 and provided an update on the Company's business and product development programs.

Financial Highlights

The Company incurred operating expenses of $13.5 million for the quarter ended September 30, 2016, with research and development accounting for $9.3 million.  This compares to operating expenses of $12.0 million for the same period of the year prior, when research and development accounted for $8.6 million. ... More